Mepolizumab as a successful steroid-sparing agent in two patients with idiopathic hypereosinophilic syndrome (iHES)

Mepolizumab as a successful steroid-sparing agent in two patients with idiopathic hypereosinophilic syndrome (iHES)

Off-label coverage of mepolizumab 100 mg q 4 weeks was approved. Since starting mepolizumab 6 months ago, her eosinophil count decreased to zero and so far, prednisone has been weaned to 5 mg daily with normalization of LFTs, maintenance of disease control and desired 22 pound weight loss. Since sta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB278-AB278
Hauptverfasser: Guo, Canting, Bochner, Bruce S.
Format: Artikel
Sprache:eng
Schlagworte:
Leukocytes (eosinophilic)
Monoclonal antibodies
Patients
Weaning
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Off-label coverage of mepolizumab 100 mg q 4 weeks was approved. Since starting mepolizumab 6 months ago, her eosinophil count decreased to zero and so far, prednisone has been weaned to 5 mg daily with normalization of LFTs, maintenance of disease control and desired 22 pound weight loss. Since starting mepolizumab 16 months ago, her eosinophil counts have been zero and she successfully tapered off prednisone 12 months ago without any recurrence of her skin involvement and some desired loss of weight.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.886